Yeo J M, Fiddian A P
J Antimicrob Chemother. 1983 Sep;12 Suppl B:95-103. doi: 10.1093/jac/12.suppl_b.95.
The efficacy of topical acyclovir in the treatment of herpes labialis has been evaluated in placebo-controlled trials with both the polyethylene glycol ointment and modified aqueous cream base preparations. Whereas a significant antiviral effect was demonstrated with acyclovir ointment in the two larger studies only favourable trends were demonstrated in the clinical parameters following early initiation of therapy. Significant clinical benefit was observed in a small single-centre study involving patients with frequent and generally more severe episodes of herpes labialis. In an animal model of experimental cutaneous herpes simplex virus infection acyclovir cream was found to be more effective than the ointment. This was confirmed in the first completed trial with acyclovir cream where a significant treatment effect was revealed on lesion duration and the inhibition of lesion development. Both topical preparations of acyclovir were well tolerated but acyclovir cream is to be preferred for the treatment of herpes labialis.
在使用聚乙二醇软膏和改良水性乳膏基质制剂进行的安慰剂对照试验中，已对局部用阿昔洛韦治疗唇疱疹的疗效进行了评估。在两项较大规模的研究中，阿昔洛韦软膏显示出显著的抗病毒效果，但在早期开始治疗后的临床参数方面，仅显示出有利趋势。在一项涉及唇疱疹发作频繁且通常更为严重的患者的小型单中心研究中，观察到了显著的临床益处。在实验性皮肤单纯疱疹病毒感染的动物模型中，发现阿昔洛韦乳膏比软膏更有效。在首个完成的阿昔洛韦乳膏试验中证实了这一点，该试验显示出对皮损持续时间和皮损发展抑制的显著治疗效果。两种阿昔洛韦局部制剂耐受性良好，但治疗唇疱疹时阿昔洛韦乳膏更受青睐。
